Ethyl pyruvate, an anti-inflammatory agent, inhibits tumor angiogenesis through inhibition of the NF-κB signaling pathway

Cancer Letters

Volumn 303, Issue 2, 2011, Pages 150-154

  Park, Shi Young ^a   Yi, Eui Yeun ^a   Jung, Myunghwan ^b   Lee, You Mie ^b   Kim, Yung Jin ^a  

^a Pusan National University   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

Angiogenesis; Anti tumor; Ethyl pyruvate; NF B

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; ETHYLPYRUVATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER MODEL; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; LEWIS CARCINOMA; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR VASCULARIZATION;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL MOVEMENT; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIAL CELLS; HUMANS; LAMININ; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROTEOGLYCANS; PYRUVATES; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 79952039854     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.12.024     Document Type: Article

References (21)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
2. Albini A., Tosetti F., Benelli R., Noonan D.M. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res. 2005, 65:100637-100641.
3. Fink M.P. Ethyl pyruvate. Curr. Opin. Anaesthesiol. 2008, 21:160-167.
4. Yang R., Gallo D.J., Baust J.J., Uchiyama T., Watkins S.K., Delude R.L., Fink M.P. Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. Am. J. Physiol. 2002, 283:G212-G221.
5. Venkataraman R., Kellum J.A., Song M., Fink M.P. Resuscitation with Ringer's ethyl pyruvate solution prolongs survival and modulates plasma cytokine and nitrite/nitrate concentrations in a rat model of lipopolysaccharide-induced shock. Shock 2002, 18:507-512.
6. Yang R., Uchiyama T., Alber S.M., Han X., Watkins S.K., Delude R.L., Fink M.P. Ethyl pyruvate ameliorates distant organ injury in a murine model of acute necrotizing pancreatitis. Crit. Care Med. 2004, 32:1453-1459.
7. dong N., Yao Y.M., Dong Y.Q., Liu H., Wei P., Yu Y., Sheng Z.Y. Effects of ethyl pyruvate on splenocyte proliferation and apoptosis in burn rats with delayed resuscitation. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2005, 17:393-396.
8. Epperly M., Jin S., Nie S., Cao S., Zhang X., Franicola D., Wang H., Fink M.P. Ethyl pyruvate, a potentially effective mitigator of damage after total-body irradiation. Radiat. Res. 2007, 168:552-559.
9. van Zoelen M.A., Bakhtiari K., Dessing M.C., van't Veer C., Spek C.A., Tanck M., Meijers J.C., van der Poll T. Ethyl pyruvate exerts combined anti-inflammatory and anticoagulant effects on human monocytic cells. Thromb. Haemost. 2006, 96:789-793.
10. Uchiyama T., Delude R.L., Fink M.P. Dose-dependent effects of ethyl pyruvate in mice subjected to mesenteric ischemia and reperfusion. Intens. Care Med. 2003, 29:2050-2058.
11. Han Y., Englert J.A., Yang R., Delude R.L., Fink M.P. Ethyl pyruvate inhibits nuclear factor-cappaB-dependent signaling by directly targeting p65. J. Pharmacol. Exp. Ther. 2005, 312:1097-1105.
12. De Martin R., Hoeth M., Hofer-Warbinek R., Schmid J.A. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler. Thromb. Vasc. Biol. 2000, 20:E83-E88.
13. Dell'Eva R., Ambrosini C., Minghelli S., Noonan D.M., Albini A., Ferrari N. The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-kappaB pathway. Carcinogenesis 2007, 28:404-413.
14. Fink M.P. Ethyl pyruvate: a novel anti-inflammatory agent. J. Intern. Med. 2007, 261:349-362.
15. Wang H., Bloom O., Zhang M., vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikona L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., Molina P.E., Abumrad N.N., Sama A., Tracey K.J. Science 1999, 285:248-251.
16. Kim S.Y., Choi J.S., Park C., Jeong J.W. Ethyl pyruvate stabilizes hypoxia-inducible factor 1 alpha via stimulation of the TCA cycle. Cancer Lett. 2010, 295:236-241.
17. Tosetti F., Ferrari N., De Flora S., Albini A. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 2002, 16:2-14.
18. Liang X., de Vivar Chavez A.R., Schapiro N.E., Loughran P., Thorne S.H., Amoscato A.A., Zeh H.J., Beer-Stolz D., Lotze M.T., de Vera M.E. Ethyl pyruvate administration inhibits hepatic tumor growth. J. Leukoc. Biol. 2009, 86:599-607.
19. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
20. De Palma M., Venneri M.A., Galli R., Sergi Sergi L., Politi L.S., Sampaolesi M., Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-216.
21. Yang L., DeBusk L.M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L.M., Carbone D.P., Lin P.C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6:409-421.